Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AK111 in healthy subjects
NCT03622021Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2018
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gumokimab in psoriasis (6 arms), sponsored by Akeso, Inc. Primary endpoint: Incidence of treatment emergent AE/SAEs at 12 weeks. Started Aug 2018; status: completed.
02
Drugs
gumokimab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03622021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03622021.